News

At the Vietnam’s Number 1 Brand 2025 announcement ceremony organized by the Asian Business Development Research Center, Genetic Analysis Services Joint Stock Company (GENTIS) was honored with the “Vietnam’s Number 1 Brand 2025” award in the genetic analysis field - Gold category, as well as the “Best Medical Product/Service for Consumers in 2025” award for the PGT-Max 1 test.

Recently, GENTIS collaborated with the Department of Andrology and Sexology at Hanoi University of Medicine to successfully organize a scientific seminar aimed at helping doctors and healthcare staff gain a better understanding of two specialized test packages: Whole Exome Sequencing (WES) and Sperm DNA Fragmentation.

In modern medicine, particularly in the diagnosis and screening of genetic diseases, the collaboration between clinical doctors, geneticists, and genetic laboratories plays an extremely important role. This is a closed-loop process that ensures patients receive accurate results, supporting the best treatment and prognosis possible.

Recently, GENTIS, in collaboration with An Viet General Hospital successfully held a scientific conference aimed at updating the information about 2 new PGT screening packages: PGT NEXT and PGT UPGRADE. At the event, a GENTIS representative provided detailed answers to the questions from doctors at the IVF An Viet Reproductive Center related these two advanced pre-implantation genetic testing packages.

Recently, the 5th-floor hall of Hanoi Andrology and Fertility Hospital collaborated with the Happy Home AF HANOI Association successfully chaired the “Happy Motherhood Journey” prenatal class. GENTIS was honored to accompany the event as a sponsor.

Thalassemia is a recessive inherited anemia disorder on the autosomal chromosome, with the highest incidence rates globally, including in Vietnam. Thalassemia causes severe consequences for the material and mental well-being of affected individuals and their families. Currently, there is no definitive cure for this disease, but proactive prevention and screening are possible. Notably, the advent of Preimplantation Genetic Testing for Monogenic Disorders (PGT-M) helps reduce the risk of having children affected by Thalassemia.

Rare diseases often lead to serious health complications and significantly affect a patient’s quality of life. Therefore, the development of PGT-M testing to screen and select embryos free of rare disease-causing genes for implantation is essential. In an effort to eliminate the fear of rare diseases from the community, GENTIS has researched and developed a PGT-M test capable of screening for over 100 rare diseases.

Clinical embryology and issues related to the IVF lab play a vital role in the advancement of Assisted Reproductive Technology (ART). The 6th Clinical Embryology Conference (CEC), organized by the Ho Chi Minh City Society for Reproductive Medicine (HOSREM), will be held on March 22–23, 2025. The conference aims to provide opportunities for professional updates, knowledge exchange, and the presentation of scientific research in the field of clinical embryology. GENTIS is honored to be a sponsor of this important event.